STATEMENT ON HOUSE SUBCOMMITTEE APPROVAL OF 340B REPORTING MANDATE
WASHINGTON, D.C.— Today, the House Energy & Commerce Committee’s Subcommittee on Health voted 16 to 12 to advance legislation (H.R. 3290) that would impose new reporting requirements on providers participating in the 340B drug pricing program. The following statement is attributed to Maureen Testoni, president and CEO of 340B Health:
“These are unnecessary and burdensome reporting requirements, and they will not paint an accurate picture of the many ways 340B savings help safety-net hospitals care for patients with low-incomes and rural communities.”
Contact: Jon Tilton at jon.tilton@340bhealth.org or 202-536-2285.